Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19.

IF 5.3 2区材料科学 Q2 MATERIALS SCIENCE, MULTIDISCIPLINARY ACS Applied Nano Materials Pub Date : 2024-12-01 Epub Date: 2022-09-13 DOI:10.1080/02648725.2022.2122290

Hayder M Al-Kuraishy, Ali I Al-Gareeb, Thabat J Al-Maiahy, Athanasios Alexiou, Nobendu Mukerjee, Gaber El-Saber Batiha

{"title":"Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19.","authors":"Hayder M Al-Kuraishy, Ali I Al-Gareeb, Thabat J Al-Maiahy, Athanasios Alexiou, Nobendu Mukerjee, Gaber El-Saber Batiha","doi":"10.1080/02648725.2022.2122290","DOIUrl":null,"url":null,"abstract":"<p><p>In response to different viral infections, including SARS-CoV-2 infection, pro-inflammatory, anti-inflammatory cytokines, and bioactive lipids are released from infected and immune cells. One of the most critical bioactive lipids is prostaglandins (PGs) which favor perseverance of inflammation leading to chronic inflammation as PGs act as cytokine amplifiers. PGs trigger the release of pro-inflammatory cytokines, activate Th cells, recruit immune cells, and increase the expression of pro-inflammatory genes. Therefore, PGs may induce acute and chronic inflammations in various inflammatory disorders and viral infections like SARS-CoV-2. PGs are mainly inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) by blocking cyclooxygenase enzymes (COXs), which involve PG synthesis. NSAIDs reduce inflammation by selective or non-selective blocking activity of COX2 or COX1/2, respectively. In the Covid-19 era, there is a tremendous controversy regarding the use of NSAIDs in the management of SARS-CoV-2 infection. As well, the possible role of PGs in the pathogenesis of SARS-CoV-2 infection is not well-defined. Thus, the objective of the present study is to review the potential role of PGs and NSAIDs in Covid-19 in a narrative review regarding the preponderance of assorted views.</p>","PeriodicalId":6,"journal":{"name":"ACS Applied Nano Materials","volume":" ","pages":"3305-3325"},"PeriodicalIF":5.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Nano Materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/02648725.2022.2122290","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

In response to different viral infections, including SARS-CoV-2 infection, pro-inflammatory, anti-inflammatory cytokines, and bioactive lipids are released from infected and immune cells. One of the most critical bioactive lipids is prostaglandins (PGs) which favor perseverance of inflammation leading to chronic inflammation as PGs act as cytokine amplifiers. PGs trigger the release of pro-inflammatory cytokines, activate Th cells, recruit immune cells, and increase the expression of pro-inflammatory genes. Therefore, PGs may induce acute and chronic inflammations in various inflammatory disorders and viral infections like SARS-CoV-2. PGs are mainly inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) by blocking cyclooxygenase enzymes (COXs), which involve PG synthesis. NSAIDs reduce inflammation by selective or non-selective blocking activity of COX2 or COX1/2, respectively. In the Covid-19 era, there is a tremendous controversy regarding the use of NSAIDs in the management of SARS-CoV-2 infection. As well, the possible role of PGs in the pathogenesis of SARS-CoV-2 infection is not well-defined. Thus, the objective of the present study is to review the potential role of PGs and NSAIDs in Covid-19 in a narrative review regarding the preponderance of assorted views.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Covid-19 中的前列腺素和非甾体抗炎药。

在对不同病毒感染（包括 SARS-CoV-2 感染）做出反应时，受感染细胞和免疫细胞会释放促炎、抗炎细胞因子和生物活性脂质。最重要的生物活性脂质之一是前列腺素（PGs），由于前列腺素是细胞因子的放大器，它有利于炎症的持续发展，导致慢性炎症。前列腺素会触发促炎细胞因子的释放，激活 Th 细胞，招募免疫细胞，并增加促炎基因的表达。因此，在各种炎症性疾病和病毒感染（如 SARS-CoV-2）中，PGs 可诱发急性和慢性炎症。非甾体抗炎药（NSAIDs）主要通过阻断涉及 PG 合成的环氧化酶（COXs）来抑制 PGs。非甾体抗炎药分别通过选择性或非选择性阻断 COX2 或 COX1/2 的活性来减轻炎症。在 Covid-19 时代，关于在治疗 SARS-CoV-2 感染中使用非甾体抗炎药存在巨大争议。此外，PGs 在 SARS-CoV-2 感染发病机制中可能扮演的角色也尚未明确。因此，本研究的目的是通过对各种观点的叙述性综述，回顾 PGs 和非甾体抗炎药在 Covid-19 中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Applied Nano Materials Multiple-

CiteScore

8.30

自引率

3.40%

发文量

1601

期刊介绍： ACS Applied Nano Materials is an interdisciplinary journal publishing original research covering all aspects of engineering, chemistry, physics and biology relevant to applications of nanomaterials. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important applications of nanomaterials.